Evidence map›Paper›PMID 35529915›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors.

Haiying Liu, Zhengyan Wang, Lijun Ren, Guiqin Zhang, Dan Zhao, Yanli Guo, Lijuan Wang, Hong Feng

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Haiying LiuDepartment of Respiratory and Critical Care Medicine, The Fourth Hospital of Baotou, Baotou City, Inner Mongolia, China.
Zhengyan WangEndoscopy Center, The Fourth Hospital of Baotou, Baotou City, Inner Mongolia, China.ORCID https://orcid.org/0000-0002-4485-0969
Lijun RenDepartment of Infectious Diseases, Baogang Third Hospital of Hongci Group, Baotou City, Inner Mongolia, China.
Guiqin ZhangDepartment of Respiratory and Critical Care Medicine, The Fourth Hospital of Baotou, Baotou City, Inner Mongolia, China.
Dan ZhaoDepartment of Respiratory and Critical Care Medicine, Hohhot First Hospital, Hohhot, Inner Mongolia, China.
Yanli GuoDepartment of Nursing, The Fourth Hospital of Baotou, Baotou City, Inner Mongolia, China.
Lijuan WangDepartment of Nephrology and Hematology, The Fourth Hospital of Baotou, Baotou City, Inner Mongolia, China.
Hong FengMedical Department, The Fourth Hospital of Baotou, Baotou City, Inner Mongolia, China.ORCID https://orcid.org/0000-0003-4221-128X
Fourth Hospital of Inner Mongolia · CNBaogang Group (China) · CNHohhot First Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To examine the clinical efficacy of budesonide/glycopyrronium bromide/formoterol (Breztri Aerosphere) as an adjunct to acute respiratory distress syndrome (ARDS). Methods: A prospective study enrolled 120 patients with pulmonary endogenous ARDS admitted to the Department of Critical Care Medicine at the Fourth Hospital of Baotou from January 2017 to January 2020, and all enrollments were assigned (1 : 1) to receive conventional treatment (control group) or Breztri Aerosphere (study group). Results: Breztri Aerosphere was associated with a significantly higher total efficacy versus conventional treatment. Breztri Aerosphere resulted in significantly lower acute physiology and chronic health evaluation scoring system (APACHE II) scores and Murray lung injury scores versus conventional treatment. Both groups saw an increase in the partial pressure of carbon dioxide (PCO2), partial pressure of oxygen (PO2), and oxygen saturation (SaO2) after treatment, with higher levels seen in patients given Breztri Aerosphere. After treatment, systemic vascular resistance (SVR) in both groups rose markedly, with greater elevation witnessed in the study group. The patients given Breztri Aerosphere showed significantly lower levels of pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (MAPA), pulmonary artery wedge pressure (PAWP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF- Conclusion: Adjuvant therapy with Breztri Aerosphere in ARDS can significantly lower APACHE II scores and Murray lung injury scores, improve blood gas indexes and pulmonary circulation function indexes, and shorten mechanical ventilation time and ICU time, which may be attributed to its improvement of organism inflammation status and reduction of inflammatory factors.

Identifiers

PMID35529915
PMCPMC9071865
OpenAlexW4285745316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.